CHMP
Champion Industries, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- +19,900.00%
- Open
- 0.0001
- Prev close
- 0.02
- Mkt cap
- 1.13K
- Vol
- 51
- Avg vol
- 0
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 0.0001
- High
- 0.0001
News
1 month ago gurufocus.com
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu
2 months ago gurufocus.com
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular d
4 months ago gurufocus.com
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
4 months ago gurufocus.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
4 months ago gurufocus.com
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro
-
16 years ago benzinga.com
US Stock Futures Face Dismal Day Again
US Stock Futures Face Dismal Day Again
-
16 years ago benzinga.com
Amgen Closer to Prolia Approval - Analyst Blog
Amgen Closer to Prolia Approval - Analyst Blog